Aktuelle Veröffentlichungen (Auswahl)

Armbrust, R., Chen, F., Richter, R., Muallem, M.Z., Mustea, A., Holthaus, B., and Sehouli, J. (2021). Results of a German wide survey towards current surgical approach in early stage cervical cancer NOGGO MONITOR 11. Sci Rep 11, 9774.

Beier, L., Faridi, A., Neumann, C., Paepke, S., Mau, C., Keller, M., Strittmatter, H.J., Gerber-Schäfer, C., Bauer, L., Karsten, M.M., et al. (2021). Human Acellular Dermal Matrix (Epiflex®) in Immediate Implant-Based Breast Reconstruction after Skin- and Nipple-Sparing Mastectomy and Treatment of Capsular Fibrosis: Results of a Multicenter, Prospective, Observational NOGGO-AWOGyn Study. Breast Care (Basel) 16, 461–467.

Blohmer, J.-U., Beier, L., Faridi, A., Ankel, C., Krause-Bergmann, B., Paepke, S., Mau, C., Keller, M., Strittmatter, H.J., and Karsten, M.M. Patient-Reported Outcomes and Aesthetic Results after Immediate Breast Reconstruction Using Human Acellular Dermal Matrices: Results of a Multicenter, Prospective, Observational NOGGO-AWOGyn Study.Breast Care.

Dimitrova, D., Naghavi, B., Richter, R., Nasser, S., Chekerov, R., Braicu, E.I., David, M., Blohmer, J., Inci, G., Torsten, U., et al. (2021). Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany.BMC Cancer 21, 1018.

Konecny, G.E., Hendrickson, A.E.W., Davidson, T.M., Winterhoff, B.J., Ma, S., Mahner, S., Sehouli, J., Fasching, P.A., Feisel-Schwickardi, G., Poelcher, M., et al. (2021). Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.Gynecol Oncol 163, 465–472.

Lee, Y.C., King, M.T., O’Connell, R.L., Lanceley, A., Joly, F., Hilpert, F., Davis, A., Roncolato, F.T., Okamoto, A., Bryce, J., et al. (2022). Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study. Int J Gynecol Cancer ijgc–2021–003142.

Marth, C., Tarnawski, R., Tyulyandina, A., Pignata, S., Gilbert, L., Kaen, D., Rubio, M.J., Frentzas, S., Beiner, M., Magallanes-Maciel, M., et al. (2022). Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. Int J Gynecol Cancer 32, 93–100.

Moore, K.N., Bookman, M., Sehouli, J., Miller, A., Anderson, C., Scambia, G., Myers, T., Taskiran, C., Robison, K., Mäenpää, J., et al. (2021). Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol 39, 1842–1855.

Musacchio, L., Salutari, V., Pignata, S., Braicu, E., Cibula, D., Colombo, N., Frenel, J.S., Zagouri, F., Carbone, V., Ghizzoni, V., et al. (2021). Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). Int J Gynecol Cancer 31, 1369–1373.

Richter, R., R., A., Woopen, H., Hilpert, F., Harter, P., and Sehouli, J. (2021). Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients. ESMO Open 6, 100081.

Sehouli, J., Mustea, A., Oskay-Özcelik, G., Keller, M., Richter, R., Tomé, O., Woopen, H., Sommer-Joos, A.-K., Grabowski, J.P., Armbrust, R., et al. (2021). Bevacizumab Combined with Platinum-Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients. Cancers (Basel) 13, 4739.

Trillsch, F., Mahner, S., Czogalla, B., Rottmann, M., Chekerov, R., Braicu, E.I., Oskay-Öczelik, G., Wimberger, P., Richter, R., and Sehouli, J. (2021). Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group.J Gynecol Oncol 32, e37.

Cookie- & Datenschutz-Einstellungen


Auch diese Webseite verwendet Cookies. Einige sind für die ordnungsgemäße Funktionalität der Webseite notwendig, andere bieten Ihnen einige Komfort-Optionen. Entscheiden Sie selbst, welche Cookies Sie akzeptieren und ob wir Daten an Drittanbieter-Server übertragen dürfen: